| CD11c+ B cells are mainly memory cells, precursors of antibody secreting cells in healthy donors ML Golinski, M Demeules, C Derambure, G Riou, M Maho-Vaillant, ... Frontiers in immunology 11, 506171, 2020 | 90 | 2020 |
| Novel biologics targeting the P2X7 ion channel F Koch-Nolte, A Eichhoff, C Pinto-Espinoza, N Schwarz, T Schäfer, ... Current Opinion in Pharmacology 47, 110-118, 2019 | 45 | 2019 |
| Evaluation of P2X7 receptor function in tumor contexts using raav vector and nanobodies (AAVnano) M Demeules, A Scarpitta, C Abad, H Gondé, R Hardet, C Pinto-Espinoza, ... Frontiers in oncology 10, 1699, 2020 | 16 | 2020 |
| A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7 In Vivo H Gondé, M Demeules, R Hardet, A Scarpitta, M Junge, C Pinto-Espinoza, ... Frontiers in Immunology 12, 704408, 2021 | 9 | 2021 |
| CD11c (+) B cells are mainly memory cells, precursors of antibody secreting cells in healthy donors. Front Immunol 11: 32 ML Golinski, M Demeules, C Derambure, G Riou, M Maho-Vaillant, ... | 7 | 2020 |
| Evaluation of nanobody-based biologics targeting purinergic checkpoints in tumor models in vivo M Demeules, A Scarpitta, R Hardet, H Gondé, C Abad, M Blandin, ... Frontiers in Immunology 13, 1012534, 2022 | 4 | 2022 |
| Development of antibody and nanobody tools for P2x7 T Stähler, W Danquah, M Demeules, H Gondé, R Hardet, F Haag, ... The P2X7 Receptor: Methods and Protocols, 99-127, 2022 | 3 | 2022 |
| Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy AC Franke, R Hardet, L Prager, M Bentler, M Demeules, P John-Neek, ... Molecular Therapy-Methods & Clinical Development 29, 238-253, 2023 | 2 | 2023 |
| Administration of an AAV vector coding for a P2X7-blocking nanobody-based biologic ameliorates colitis in mice C Abad, M Demeules, C Guillou, H Gondé, R Zoubairi, YV Tan, ... Journal of Nanobiotechnology 22 (1), 1-18, 2024 | | 2024 |
| Blood Donation Guide Contact Search C Abad, M Demeules, C Guillou, H Gondé, R Zoubairi, Y Tan, ... J NANOBIOTECHNOL 22 (1), 27, 2024 | | 2024 |
| AAV-mediated induction of immunogenic cell death to promote anti-tumor immune responses A Scarpitta, R Hardet, M Bentler, M Demeules, M Blandin, U Hacker, ... HUMAN GENE THERAPY 33 (23-24), A7-A7, 2022 | | 2022 |
| Le récepteur P2X7: évaluation de cette cible thérapeutique dans les pathologies inflammatoires et dans le cancer M Demeules Normandie, 2022 | | 2022 |
| Towards a single-shot prime-boost AAV-based vaccine for cancer immunotherapy A Franke, R Hardet, L Prager, M Bentler, M Demeules, N Jaeschke, ... HUMAN GENE THERAPY 32 (19-20), A34-A34, 2021 | | 2021 |
| Characterization of CD11c+ B-cells from human blood SF Calbo, M Demeules, C Derambure, G Riou, M Vaillant, O Boyer, P Joly, ... The Journal of Immunology 202 (1_Supplement), 179.6-179.6, 2019 | | 2019 |
